SeaCrest Wealth Management’s AbbVie ABBV Stock Holding History

SeaCrest Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.21M	Sell	8,765 -4,426	-34%	-$952K	0.24%	79
2026 Q1	$2.87M	Sell	13,191 -770	-6%	-$171K	0.31%	61
2025 Q4	$3.26M	Sell	13,961 -279	-2%	-$63.6K	0.33%	51
2025 Q3	$3.29M	Sell	14,240 -2,696	-16%	-$549K	0.35%	51
2025 Q2	$3.14M	Sell	16,936 -3,431	-17%	-$638K	0.34%	57
2025 Q1	$4.27M	Sell	20,367 -17	-0.1%	-$3.31K	0.48%	32
2024 Q4	$3.62M	Sell	20,384 -1,890	-8%	-$347K	0.38%	36
2024 Q3	$4.4M	Buy	22,274 +679	+3%	+$127K	0.47%	31
2024 Q2	$3.7M	Buy	21,595 +201	+0.9%	+$33.3K	0.42%	35
2024 Q1	$3.9M	Sell	21,394 -2,510	-11%	-$433K	0.48%	35
2023 Q4	$3.88M	Sell	23,904 -338	-1%	-$49.3K	0.48%	37
2023 Q3	$3.61M	Sell	24,242 -691	-3%	-$101K	0.47%	38
2023 Q2	$3.36M	Sell	24,933 -9,863	-28%	-$1.45M	0.42%	41
2023 Q1	$5.55M	Sell	34,796 -1,531	-4%	-$234K	0.75%	19
2022 Q4	$5.87M	Sell	36,327 -2,747	-7%	-$421K	0.84%	17
2022 Q3	$5.24M	Sell	39,074 -12,715	-25%	-$1.82M	0.8%	19
2022 Q2	$7.93M	Sell	51,789 -313	-0.6%	-$47.8K	1%	8
2022 Q1	$8.45M	Buy	52,102 +1,000	+2%	+$145K	0.97%	11
2021 Q4	$6.92M	Buy	51,102 +1,532	+3%	+$181K	0.76%	18
2021 Q3	$5.35M	Buy	49,570 +10,731	+28%	+$1.23M	0.65%	27
2021 Q2	$4.38M	Buy	38,839 +73	+0.2%	+$8.22K	0.53%	32
2021 Q1	$4.2M	Sell	38,766 -7,333	-16%	-$784K	0.56%	32
2020 Q4	$4.94M	Buy	46,099 +1,667	+4%	+$160K	0.69%	25
2020 Q3	$3.89M	Sell	44,432 -825	-2%	-$77.7K	0.62%	32
2020 Q2	$4.44M	Buy	45,257 +10,606	+31%	+$934K	0.77%	21
2020 Q1	$2.64M	Buy	34,651 +2,527	+8%	+$215K	0.57%	38
2019 Q4	$2.84M	Sell	32,124 -259	-0.8%	-$21.5K	0.48%	47
2019 Q3	$2.45M	Buy	32,383 +2,539	+9%	+$174K	0.46%	45
2019 Q2	$2.17M	Sell	29,844 -4,017	-12%	-$316K	0.44%	50
2019 Q1	$2.73M	Buy	33,861 +3,070	+10%	+$251K	0.47%	39
2018 Q4	$2.84M	Sell	30,791 -5,338	-15%	-$469K	0.59%	29
2018 Q3	$3.42M	Buy	36,129 +1,314	+4%	+$125K	0.58%	28
2018 Q2	$3.23M	Buy	34,815 +10,483	+43%	+$1.02M	0.58%	29
2018 Q1	$2.3M	Sell	24,332 -2,682	-10%	-$295K	0.42%	50
2017 Q4	$2.61M	Buy	+27,014	New	+$2.55M	0.48%	40

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

CRM

Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

SeaCrest Wealth Management's ABBV Position: Q2 2026 in Review

SeaCrest Wealth Management reduced its AbbVie (ABBV) stake by 34% in Q2 2026, selling an estimated $952K and leaving 8,765 shares worth $2.21M. The position accounts for 0.24% of the portfolio, ranked #79.

SeaCrest Wealth Management first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. The position peaked at $8.45M in Q1 2022. 1,042 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

SeaCrest Wealth Management held 8,765 shares of AbbVie worth $2.21M as of Q2 2026.
SeaCrest Wealth Management sold 4,426 AbbVie shares in Q2 2026, an estimated $952K.
AbbVie made up 0.24% of SeaCrest Wealth Management's portfolio in Q2 2026, its #79 holding.
SeaCrest Wealth Management first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
SeaCrest Wealth Management's AbbVie position peaked at $8.45M in Q1 2022.
1,042 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on SeaCrest Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.